American Herbal Products Association (AHPA) > Resources > Regulations > Government Advocacy

Recent AHPA Advocacy

Request for proposals: Slippery elm sustainable wild harvest study

Request for proposals: Slippery elm sustainable wild harvest study

Submission Deadline: July 1, 2020

The AHPA Foundation for Education and Research on Botanicals (AHPA ERB Foundation) is issuing a request for proposals to award grant funding to eligible applicants in order to enhance and promote knowledge and understanding of sustainable harvest of slippery elm (Ulmus rubra).  The grant supports research effects of varying rates of wild slippery elm bark harvest on tree population health and recovery across multiple harvest sites in order to inform sustainable harvest and management decisions for the species. The anticipated amount of funding available for a sustainable wild slippery elm bark harvest research project is up to $10,000 annually for up to 5 years.

AHPA Hemp-CBD Status Report

Updated in April 2020 to cover recent FDA and USDA actions

To help the herbal products industry understand the evolving regulatory landscape for hemp and hemp-derived cannabidiol (CBD) products, AHPA has updated its free Hemp-CBD Status Report to include recent actions taken by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA).

AOAC Scientists Approve Official Method of Analysis for Cannabinoids in Hemp

AHPA Chief Science Officer Dr. Holly Johnson chairs CASP working group involved creating requirements for testing standard

The new validation and approval will allow laboratories to evaluate hemp for tetrahydrocannabinol (THC) on a dry-weight basis, as described by the U.S. Department of Agriculture’s Interim Final Rule governing the production of hemp under the 2018 Agriculture Improvement Act, known as the Farm Bill.

Oregon adopts temporary rule prohibiting unsubstantiated claims that goods prevent, treat, diagnose, or mitigate COVID-19 related conditions

AHPA has been working with other trade organizations to seek withdrawal of a much-broader proposed rule that the OR DOJ published for comment late last year and in amended form in March 2020.

The Oregon Department of Justice (OR DOJ) has temporarily adopted a rule declaring it “unfair and deceptive” (and thus unlawful) to represent that any product “will prevent, treat, diagnose, mitigate, or cure coronavirus, COVID-19 or a related condition, without first having competent and reliable scientific evidence upon which to base a reasonable belief in the truth of the representation.” The temporary rule is effective for six months, until October 14, 2020.

AHPA and CRN express concern about Proposed Rule in Oregon that would create private right of action for opportunistic plaintiffs’ lawyers

AHPA and CRN urge that Oregon Proposed Rule is unnecessary and should be withdrawn

AHPA and the Council for Responsible Nutrition (CRN) filed joint comments last week to reiterate significant concerns to the Oregon Department of Justice (OR DOJ) about a Proposed Rule that would create a private right of action for opportunistic plaintiffs' lawyers motivated by the potential for recovery rather than the public interest.

AHPA submits supply chain issues to USDA and continues to collect industry data

Report your supply chain issues to AHPA using this brief survey

AHPA has reported to the U.S. Department of Agriculture (USDA) a host of supply chain issues submitted by members and others in the herbal community. The information submitted to USDA reports on shortages or delivery disruptions of a variety of ingredients, supplies, and services. AHPA also continues to collect supply chain data to inform the industry, regulators and lawmakers.

Supplement Industry Associations Applaud FDA Actions to Protect Consumers from Fraudulent Products Related to Coronavirus Disease (COVID-19)

Washington D.C., April 6, 2020

The U.S. dietary supplement industry commends the Food and Drug Administration (FDA) for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. In February, the industry issued strong warning to companies and consumers to avoid marketing or using dietary supplements that are presented as treating, curing or preventing COVID-19.

IADSA update on international supplement regulations

IADSA update on international supplement regulations

April 2020 IADSA Newsflash

This issue of the IADSA Newsflash covers the European Commission's draft regulation directed at botanicals containing hydroxyanthracene derivatives (HADs), Belgium recently published guidance on the analysis for four new plants, Ireland survey of cannabidiol (CBD) products that found a majority were not in compliance with various regulations, Norway's risk assessment of caffeine and more.

DHS-CISA updates their guidance, cites "dietary supplement" workers as essential critical infrastructure workers

Revised guidance provides numerous and significant additional details in identifying essential critical infrastructure workers and sectors

Revised guidance provides numerous and significant additional details in identifying essential critical infrastructure workers and sectors in several categories, including, among others, healthcare, law enforcement, transportation, and food and agriculture.

Dietary supplement, other herbal product, and cannabis operations identified as “essential businesses” and “critical infrastructure”

Designation implied by numerous regulatory agencies; explicit in California

Federal, state, and local governments’ actions to address the novel coronavirus and COVID-19 have consistently included recommendations promoting or directives requiring social distancing as a key protective measure to minimize community spread of this disease. In making stay-at-home recommendations or issuing shelter-in-place orders, health agencies and other official bodies have identified certain industries as “essential businesses” or “critical infrastructure” whose employees and operations are (or should be) exempt from these recommendations and directives.
RSS
12345678910 Last

2020 Annual Fund Sponsors

   

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.